HC Wainwright Reaffirms Buy Rating for LAVA Therapeutics (NASDAQ:LVTX)

HC Wainwright restated their buy rating on shares of LAVA Therapeutics (NASDAQ:LVTX) in a research report released on Friday morning, Benzinga reports. The firm currently has a $6.00 price target on the stock.

Separately, JMP Securities restated a market outperform rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research note on Wednesday, August 23rd.

LAVA Therapeutics Stock Performance

Shares of LAVA Therapeutics stock opened at $1.50 on Friday. LAVA Therapeutics has a 12-month low of $1.13 and a 12-month high of $7.38. The stock has a market cap of $38.03 million, a P/E ratio of -0.78 and a beta of -0.24. The company has a quick ratio of 5.31, a current ratio of 5.31 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $1.43 and its 200-day moving average is $1.74.

LAVA Therapeutics (NASDAQ:LVTX) last announced its quarterly earnings data on Thursday, November 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.15. LAVA Therapeutics had a negative return on equity of 67.23% and a negative net margin of 557.33%. The company had revenue of $0.05 million for the quarter. Equities research analysts predict that LAVA Therapeutics will post -1.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LAVA Therapeutics

A number of large investors have recently added to or reduced their stakes in LVTX. Renaissance Technologies LLC acquired a new position in LAVA Therapeutics in the 4th quarter valued at $66,000. Bank of America Corp DE grew its holdings in LAVA Therapeutics by 20,566.7% in the 1st quarter. Bank of America Corp DE now owns 32,240 shares of the company’s stock valued at $54,000 after buying an additional 32,084 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in LAVA Therapeutics by 30.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 65,000 shares of the company’s stock valued at $132,000 after buying an additional 15,000 shares in the last quarter. Finally, Bruce & Co. Inc. acquired a new position in LAVA Therapeutics in the 4th quarter valued at $350,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.